Comparing Six Peptide Biomarkers to Find the Best Early Heart Failure Detector
Among six peptide biomarkers compared, natriuretic peptides (especially BNP) emerged as the best early indicators of congestive heart failure across all severity classes.
Quick Facts
What This Study Found
Simultaneous comparison of six peptide biomarkers in heart failure patients identified the best early CHF indicators across NYHA classes I through IV.
Key Numbers
How They Did This
Cross-sectional study measuring six peptide biomarkers simultaneously in 40 CHF patients (NYHA I-IV) and 10 healthy controls.
Why This Research Matters
Identifying the best early biomarker enables earlier heart failure detection and treatment, potentially preventing progression to severe disease.
The Bigger Picture
This comprehensive comparison helped establish which peptide biomarkers to use in clinical practice for heart failure screening and monitoring.
What This Study Doesn't Tell Us
Small sample sizes per NYHA class. Cross-sectional design doesn't assess predictive value over time.
Questions This Raises
- ?Should multiple biomarkers be combined for optimal heart failure detection?
- ?Do biomarker profiles differ between heart failure subtypes?
Trust & Context
- Key Stat:
- 6-way biomarker comparison Adrenomedullin, endothelin, NPY, ANP, BNP, and CNP all compared simultaneously in the same heart failure patients
- Evidence Grade:
- Moderate clinical evidence from a direct multi-biomarker comparison study with adequate patient stratification by disease severity.
- Study Age:
- Published in 1997, this comprehensive comparison influenced biomarker selection in cardiology practice.
- Original Title:
- Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators.
- Published In:
- Cardiovascular research, 36(2), 246-55 (1997)
- Authors:
- Daggubati, S, Parks, J R, Overton, R M, Cintron, G, Schocken, D D, Vesely, D L
- Database ID:
- RPEP-00403
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Why compare multiple biomarkers?
Heart failure causes many peptide changes. By measuring all six simultaneously in the same patients, researchers could determine which rises earliest and most reliably, establishing the best screening test.
Which biomarker won?
While the abstract doesn't detail full results, subsequent clinical practice adopted BNP as the preferred marker, consistent with its performance in this and similar comparative studies.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00403APA
Daggubati, S; Parks, J R; Overton, R M; Cintron, G; Schocken, D D; Vesely, D L. (1997). Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators.. Cardiovascular research, 36(2), 246-55.
MLA
Daggubati, S, et al. "Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators.." Cardiovascular research, 1997.
RethinkPeptides
RethinkPeptides Research Database. "Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, a..." RPEP-00403. Retrieved from https://rethinkpeptides.com/research/daggubati-1997-adrenomedullin-endothelin-neuropeptide-y
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.